Investigational New Drug Application
Shares of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) hit a new 52-week low of $4.72 on Monday and was trading lower by more than 4 percent. Ariad Pharmaceuticals announced earlier in the day that the U.S. Food and Drug Administration has completed its review of the companys Investigational New... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:
Scopus Biopharma Inc Ariad Pharmaceuticals Drug Administration Ariad Pharmaceuticals Inc Diamedica Therapeutics Inc Investigational New Drug Application
Source: benzinga.com